Objective: To report the identification of microtubule-associated protein (MAP) 1B as the antigen of the previously described Purkinje cell cytoplasmic antibody type 2 (PCA-2) antibody, its frequency, and clinical, oncological, and serological associations. Methods: Archival serum or cerebrospinal fluid (CSF) specimens were available from 96 of 118 consecutive PCA-2-IgG-seropositive patients identified during 1993-2016. The autoantigen, defined in mouse brain lysate by Western blot and mass spectrometry, was confirmed by dual immunohistochemical staining using commercial antibodies. The major antigenic region was defined by Western blot using recombinant protein fragments. Results: IgG in 95 of 96 patients' serum or CSF (but in none of 98 healthy or disease control subjects' serum specimens) bound to recombinant MAP1B. A minority (17.5%) of patients' IgG also bound to MAP1A. PCA-2 was often accompanied by additional neural autoantibody markers of small-cell carcinoma, including collapsin responsemediated protein 5 (CRMP5) IgG (26%) or antineuronal nuclear antibody type 1 (ANNA-1) IgG (also known as antiHu; 13%). Neurological manifestations in 95 patients were (in decreasing frequency): peripheral neuropathy, 53%; cerebellar ataxia, dysmetria, or dysarthria, 38%; and encephalopathy, 27%. Cancer (majority small-cell lung carcinoma [SCLC]) was detected in 66 of 84 evaluated patients (79%). The MAP1B (PCA-2) autoantibody detection rate, among approximately 70,000 patients undergoing service neural autoantibody evaluation in 2015, was 0.024%, equaling amphiphysin IgG (0.026%) and more common than ANNA-2 (also known as anti-Ri; 0.016%) and PCA-Tr (also known as delta/notch-like epidermal growth factor-related receptor [DNER]; 0.006%). Interpretation: MAP1B, the PCA-2 autoantigen, represents a novel target in paraneoplastic neurological disorders and has high predictive value for SCLC. Its relatively high prevalence, compared with other recognized paraneoplastic neural autoantibodies, justifies its testing in comprehensive paraneoplastic neural autoantibody evaluation. ANN NEUROL 2017;81:266-277 I n 2000, Vernino and Lennon 1 reported 10 patients with neurological autoimmunity, 9 of whom had imaging or histopathologic evidence of lung cancer (8 biopsyproven small-cell lung carcinoma [SCLC]). Their serum IgG bound to a protein of 280kDa mass in both rodent brain and a SCLC line and yielded a characteristic staining pattern on rodent neural tissues. The autoantibody was named Purkinje cell cytoplasmic antibody type 2 (PCA-2), to distinguish it from a biomarker of ovarian and breast cancer-related cerebellar degeneration, PCA-1 (also known as anti-Yo).
with neurological autoimmunity, 9 of whom had imaging or histopathologic evidence of lung cancer (8 biopsyproven small-cell lung carcinoma [SCLC] ). Their serum IgG bound to a protein of 280kDa mass in both rodent brain and a SCLC line and yielded a characteristic staining pattern on rodent neural tissues. The autoantibody was named Purkinje cell cytoplasmic antibody type 2 (PCA-2), to distinguish it from a biomarker of ovarian and breast cancer-related cerebellar degeneration, PCA-1 (also known as anti-Yo). 2 The neurological associations initially reported for PCA-2 were mixed, of subacute onset and predominantly central (brainstem and limbic encephalitis, cerebellar ataxia), but some patients had peripheral manifestations (Lambert-Eaton myasthenic syndrome [LEMS] or autonomic or motor neuropathy). 1 Our study extends the immunochemical characteristization of PCA-2 IgG and identifies its antigen as MAP1B, a member of the microtubule-associated protein family. We also provide clinical and oncologic correlative information gained for this paraneoplastic autoantibody in the past 2 decades. ANTIBODY PURIFICATION. Cerebellar proteins separated electrophoretically in 5% polyacrylamide gel were transferred electrophoretically to nitrocellulose membrane, and blocked in buffer (20mM Tris, pH 7.6, 137mM sodium chloride, 0.1% Tween-20) containing 10% powdered milk. Longitudinal edge strips (0.5cm) were cut from the nitrocellulose and probed with patient IgG to locate the immunoreactive band (320kDa). The remaining nonexposed central region of the nitrocellulose, containing the reactive band (9.5 3 0.8cm), at approximately 320kDa, was cut horizontally, and a control strip was cut from a nonreactive region. Patient serum (diluted 1:500) was applied to the cut nitrocellulose strips. After 1 hour, and extensive washing, bound "affinity-purified" human IgG was eluted in 100mM acetic acid, neutralized, dialyzed against PBS, and concentrated. The eluted IgG was tested by indirect immunofluorescence assay (IFA) on mouse tissue sections to confirm PCA-2 specifity. beads (Dynabeads; Invitrogen, Carlsbad, CA; Thermo Fisher Scientific) and exposed to cerebellar protein extract (1 hour). After washing, beads were boiled for 5 minutes in 2 3 sample buffer. Eluted sample was electrophoresed in 5% polyacrylamide gel, and proteins were located by Coomassie G-250 staining (Bio-Rad) and by Western blot. The immunoreactive band was excised from the stained gel, reduced, alkylated with iodoacetamide, and digested with trypsin. Peptides in the digested sample were analyzed using nano high-pressure liquid chromatography electrospray tandem mass spectrometry.
Patients and Methods

Patients
CONSTRUCTS. cDNA encoding full-length MAP1A and MAP1B proteins (Genecopoeia clone # HOC23132 and HOC23292) were used as templates for amplification reactions using either Pfx (Invitrogen) or AmpliTaq (Applied Biosystems, Foster City, CA) DNA polymerase. The coding regions of both genes were amplified as 5 individual fragments (Table 1 ) and cloned into pET102D bacterial expression vector (Invitrogen). Clones were selected, and sequence integrity was verified by Sanger sequencing. BL-21 cells (Invitrogen) were transformed with plasmid DNA, grown under antibiotic selection, and at optical density 0.5 to 0.8 were induced with isopropyl thiogalactoside (400mM). After 2.5 hours at 37 8C, cells were pelleted and protein expression was verified by extraction (50mM NaPO 4 , 400mM NaCl, 100mM KCl, 10% glycerol, 0.5% Triton X-100, 10mM imidizole) and Western blot (horseradish peroxidase-conjugated V5 epitope tagspecific IgG [Invitrogen]).
Absorption of Patient Serum with MAP1B
Following incubation with bovine liver powder, 50 ml of serum from 2 PCA-2-IgG-positive patients (Patients 74 and 82, Supplementary Table 1 ) and 1 control patient positive for antineuronal nuclear antibody type 1 (ANNA-1; also known as anti-Hu) were incubated with 10 ml of recombinant MAP1B protein, fragment 1, overnight. Postincubation sera were tested by IFA on mouse tissue sections.
Results
Characterization of the Autoantibody
IMMUNOHISTOCHEMICAL DISTRIBUTION OF THE NEURAL ANTIGEN. The initial report of PCA-2 IgG noted striking cytoplasmic staining on cerebellar Purkinje neuronal perikaryon and dendrites, dentate neurons, myenteric ganglia and enteric nerves (extending into gastric mucosa), and sympathetic nerves innervating kidney (Fig 1A-D) . Examination of additional central nervous system regions represented in the presently extended mouse tissue substrate revealed a diffuse glow over synapse-rich regions of cerebral cortex and hippocampus and staining of dendrites of hippocampal pyramidal neurons (mostly CA-1) and cerebral cortex.
IMMUNOCHEMICAL CHARACTERIZATION OF THE AUTOANTIGEN. PCA-2 IgG Binds to a 320kDa
Native Neural Protein. Western blot probing of mouse brain proteins with patient IgGs confirmed a common immunoreactive band, 320kDa; control human IgGs were nonreactive (see Fig 1G) . IgG eluted from the immunoreactive region of nitrocellulose, but not from a Confocal Microscopy Supports MAP1B as Primary Antigenic Target. Commercial IgG specific for MAP1B yielded a staining pattern on mouse tissues identical to that of patient IgG (Fig 2) . MAP1A-specific IgG yielded a similar pattern in some but not all nervous system regions (Fig 3) . The staining pattern yielded by MAP2 and MAP2B IgG did not resemble that of patient IgG (not shown).
Western Blot Characterization of the Antigen. In Western blot analyses, commercial anti-MAP1B antibodies bound to a protein of the same electrophoretic mobility as that identified by the patient's IgG ( Fig 4A,  B) ; MAP1A and MAP2/2B both differed, as predicted. 6 Although the mobility of the lower band of the doublet (see Fig 4A, B) is similar to MAP2/2B on Western blot, those proteins share 4 or fewer amino acids with sequence identity to MAP1B. Based on these, we 2) binds in Western blots (7.5% gel) to a common band (320kDa, by reference to molecular weight standards); IgG in serum of a healthy control subject does not bind (lane 3). To verify specificity, patient IgG was affinity purified on the putative antigenic band and a control band. (H, I) Application of IgG eluted from a nitrocellulose strip containing the 320kDa protein to mouse tissue substrates reproduced the original PCA-2 immunostaining pattern of whole patient serum on cerebellar cortex (H), cerebral cortex and enteric nervous system (I; compare A-F).
concluded that the lower band seen on Western blot was a proteolytic fragment of the MAP1B protein.
The MAP1B precursor polypeptide contains at its C-terminus the post-translationally cleaved light chain (LC1), which commercial antibodies recognize as a 32kDa band. None of the tested patients' sera bound to a band of that size (Western blot, not shown). MAP1A genes were each amplified as 5 individual fragments (see Table 1 ) overlapping by approximately 60 to 70 residues (see Supplementary Table 1 ). Sera (diluted 1:500) or CSF (diluted 1:50) from 40 PCA-2-IgG-positive patients were tested by Western blot on all 10 fragments (MAP1A # 1-5, MAP1B # 1-5) for polypeptide-reactive IgG. IgG in 40 of 40 specimens bound to MAP1B fragment 1 (see Fig 4C, D) , IgG in 19 of 40 sera bound to MAP1B fragment 2, and small minority bound to other MAP fragments (see Fig 4D) . IgG in 55 of the remaining 56 PCA-2-IgG-positive sera bound to MAP1B fragment 1 (1 moderately reactive).
Twenty-seven of the 40 sera tested with all MAP fragments bound to a synthetic peptide encompassing residues 540 to 693, containing the overlap sequence common to MAP1B fragments 1 and 2 (see Table 1 , Supplementary Table 1, and Fig 4D) . PCA-2-IgG staining pattern (Fig 5A-C) . This preincubation did not diminish the immunostaining intensity of ANNA-1 IgG in serum of a control patient with SCLCrelated paraneoplastic neurological autoimmunity (see Fig  5D) .
DIVERSE NEUROLOGIC ACCOMPANIMENTS OF
MAP1B (PCA-2) AUTOIMMUNITY. Clinical information was available for 95 patients ( Table 2 , Supplementary Table 2 ). The median age at neurological symptoms onset was 68 years (range 5 22-89); 55 patients (47%) were women, and 82% (55 of 67) had a history of tobacco use. Neurological presentations varied, and symptoms and signs in the majority of cases were subacute in onset (61%). Peripheral neuropathy was the most common presentation, being reported in 50 patients (53%); 44 had sensory-motor neuropathy (confirmed by electromyography in 16), 14 had dysautonomia, and 34 patients had additional involvement of the central nervous system. Cerebellar dysfunction was reported in 36 patients (38%). Cortical/subcortical involvement also was commonly encountered; encephalopathy/cognitive decline was reported in 26 patients (27%), 5 of whom had seizures.
Ten patients had symptoms referable to the anterior visual system. The following findings were documented in the medical/laboratory records: disk edema in 3, optic nerve involvement in 4 (3 with neuritis collapsin response-mediated protein 5 [CRMP5] IgG), enhancement of optic nerves on magnetic resonance imaging (MRI) in 2 (1 with CRMP5 IgG), retinopathy in 5 (3 with CRMP5 IgG).
Coexisting neural antibodies were detected in 79 of 118 patients (67%, Table 3 ). Most common were CRMP5 IgG (26%) and voltage-gated calcium channel antibodies (22%).
Reports of MRI brain and spinal cord were available for review in 43 patients; 15 (35%) were normal, 8 (19%) had nonspecific white matter changes, and 20 (46%) had more extensive changes considered pathological (Table 4 ). The most common disease-relevant findings were spinal cord involvement (5 with T2 hyperintensities, 3 with enhancement), cerebral atrophy (n 5 4), optic nerve involvement (n 5 2, 1 with enhancement), and temporal lobe involvement (n 5 2). MAP1B (PCA-2) IgG was the sole autoantibody detected in 4 of 5 patients with spinal cord involvement, 2 of 2 patients with meningeal enhancement, and 1 of 2 patients with optic nerve involvement (CRMP5 IgG coexisted with MAP1B IgG in the second patient with optic nerve involvement). More than half of the patients with cerebellar/cerebral atrophy or temporal involvement had additional antibodies including CRMP5 IgG and ANNA-1.
Results of CSF examination were available for 29 patients; 15 (52%) had pleomorphic leukocytosis (median white cell count 5 20, range 5 6-162, normal reference range 5 per high-power field); 21 (74%) had elevated protein (median 5 60mg/dl, range 5 37-203, normal 35mg/dl).
ONCOLOGIC ASSOCIATIONS OF MAP1B IgG. Among 84 patients with adequate information concerning oncologic evaluation, cancer was found in 66 (79%; Table 5 ). >1 coexisting 10 [9] a Data available for 117 patients. b None of 96 available sera was positive for LGI1 (leucine-rich, glioma inactivated 1) IgG or CASPR2 (contactin-associated proteinlike 2) IgG.
ANNA 5 antineuronal nuclear antibody; AChR 5 acetylcholine receptor; AGNA 5 antiglial/neuronal nuclear antibody; AMPA 5 a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate; CRMP 5 collapsin response-mediated protein; GABA 5 c-aminobutyric acid; GAD 5 glutamic acid decarboxylase; MAP 5 microtubule-associated protein; PCA 5 Purkinje cell cytoplasmic antibody; VGCC 5 voltage-gated calcium channel; VGKC 5 voltage-gated potassium channel.
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The cancer detection frequency was higher in 44 patients who were singularly seropositive for MAP1B IgG (89%). Lung cancer was the most common of all cancers (80%). SCC was 3 times more common than non-small-cell lung carcinoma (46% and 16%, p < 0.01). Cancer diagnosis followed the neurological presentation in 55% of cases. Adequate follow-up information was available for 14 of 39 patients with SCLC. Their median survival was 54 months (range 5 3-164). Commercial MAP1B-specific IgG confirmed MAP1B-immunoreactive protein in 6 of 10 SCLC tumor cell lines. Data regarding response to immunotherapy were available for only 26 patients, of whom 14 had physician-reported benefit from immunosuppression (neurological symptoms stabilized or improved). Beneficial responses were reported for 8 of 16 receiving corticosteroids, 3 of 4 receiving plasmapheresis, 2 of 2 receiving cyclophosphamide, and none of 2 receiving high-dose intravenous immune globulin. Some neurologic benefit was reported in 11 of 15 patients following cancer chemotherapy.
Discussion
Our study has identified MAP1B as the antigen of a neuronal autoantibody initially named PCA-2, which is a strong predictor of SCLC and a biomarker for paraneoplastic neurological disorders with diverse neurological manifestations. Preliminary epitope mapping localized the dominant antigenic region within the initial 700 Nterminal residues of MAP1B. The frequency of MAP1B IgG is equivalent to that of amphiphysin IgG as a marker of paraneoplastic autoimmunity (the latter predicts either SCLC or breast adenocarcinoma) and exceeds that of ANNA-2 IgG (also known as anti-Ri; also a predictor of either lung or breast carcinoma) or PCA-Tr IgG (marker of immune response to Hodgkin lymphoma). As is often the case for paraneoplastic neural antibodies, MAP1B IgG commonly coexists with other neural autoantibodies. 8 The strong positive predictive value of MAP1B IgG for SCC accounts for its frequent coexistence with other autoantibody biomarkers of SCLC, CRMP5 IgG in 26% of cases and ANNA-1 in 13% of cases. The frequency of lung cancer detection was similar in MAP1B-IgG-seropositive patients, regardless of coexisting onconeural autoantibodies (66% and 63%, respectively). Four of 8 patients with optic nerve or retinal involvement (1 had both) had coexisting CRMP5 IgG. Optic neuritis and retinitis are a recognized syndromic manifestation of CRMP5 autoimmunity. 9 Nevertheless, for cases lacking CRMP5 IgG, it is noteworthy that the MAP1B antigen is expressed in the retina and that mice genetically lacking MAP1B have retinal dysfunction as a phenotypic manifestation. [10] [11] [12] Neurological manifestations noted in 5 MAP1B-IgG-seropositive patients (chorea, 3; dystonia, 1; dyskinesia, 1) were plausibly attritutable in 4 to coexisting autoimmunity to other SCLC onconeural antigens. 13 Three patients who were CRMP5 IgG positive had chorea; a fourth patient with coexisting amphiphysin IgG had dystonia. The fifth patient was singularly MAP1B IgG positive, and had orofacial dyskinesia with constant bilateral dyskinetic movements in arms and legs and MRI evidence of caudate nucleus atrophy (see Tables 2, 4 ).
All 4 patients with LEMS and sufficient clinical data had SCLC. These data are consistent with MAP1B IgG positivity being indicative of a paraneoplastic basis for LEMS, as is recognized for SOX1 IgG 14 and ANNA-1.
15
MAP1B is the first microtubule-associated protein identified as a target of paraneoplastic neurological autoimmunity. The neuronal cytoskeleton is essential for organizing and maintaining shape, cellular function and polarity, including axonal transport, regional specialization, and synapse formation. 16, 17 The microtubular cytoskeleton is fundamental to the development and function of axons and dendrites and provides the major track for intracellular transport. Microtubule-associated proteins, including MAP1, MAP2, and tau, bind and stabilize microtubules. 18, 19 High-molecular-mass microtubuleassociated proteins, MAP1A and MAP1B, are expressed predominantly in the nervous system. 20, 21 MAP1B expression peaks during early stages of neuronal development [22] [23] [24] [25] [26] [27] [28] and plays an important role in neuronal differentiation, including dendritic spine formation and synaptic maturation. [29] [30] [31] [32] [33] [34] [35] [36] In the adult brain, MAP1B is 
Gadoth et al: MAP1B IgG
February 2017 275 retained in areas with high synaptic plasticity. 37 The delayed nervous system development, abnormal neuronal morphology, lack of corpus callosum, and susceptibility to perinatal death in mice with genetically deleted MAP1B support its central role in neuronal development. 32, 33, 36 Although MAP1B is recognized as an intracellular protein, several studies in cultured neurons have indicated that rather than being restricted to the cytoskeleton, a significant fraction is in the cytosol. 30, [38] [39] [40] Some evidence supports its partial expression as a neuronal plasma membrane glycoprotein in neurons, 40 a location that would be accessible for interaction with a MAP1B-specific IgG. However, the lack of significant beneficial response observed in seropositive patients receiving antibody-lowering therapies does not favor a pathogenic role for MAP1B IgG. Like other onconeural autoantigens, MAP1B is highly expressed both in developing neurons and in neuroendocrine tumors. Its expression in mature synapses plausibly explains the staining of the neuropil noted throughout the mouse nervous system and is reminiscent of that seen with amphiphysin and CRMP5. 5, 41, 42 The widespread distribution of MAP1B throughout the central and peripheral nervous systems is consistent with the diverse and multifocal neurologic impairment observed with PCA-2 autoimmunity. 40 Amino acid sequence homologies of MAP1A and MAP1B (see Supplementary Table 1 ) would account for the reactivity of patient IgG with MAP1A protein in some cases. Acknowledging the limited survival data and the possible impact of lead time bias, the 54-month median survival of SCLC patients for whom follow-up data were available far exceeds the 7 to 12 months reported for SCLC patients diagnosed with extensive stage disease and 23 months for patients with limited-stage disease. 43, 44 Precedent knowledge from experience with autoantibodies specific for other intracellular antigens predicts that MAP1B IgG represents a surrogate marker of a concurrent and robust cytotoxic CD8 1 T-cell response targeting peptides derived from MAP1B protein, initiated by MAP1B in a patient's cancer. 45 The detection frequency for MAP1B IgG (PCA-2) in the Mayo Clinic Neuroimmunology Laboratory in the past year (17 patients [0.024%] among approximately 70,000 screened for IgG markers of paraneoplastic neural autoimmunity on a service basis) approximated that of amphiphysin IgG (18 among 70,000 [0.026%]) and exceeded that of ANNA-2 (also known as AntiRi; 11 [0.016%]) and PCA-Tr (also known as DNER; 4 [0.006%]). Furthermore, the diversity of MAP1B-IgGassociated paraneoplastic neurological presentations with potential for immunotherapy responsiveness, and its high predictive value for SCLC, justify screening for MAP1B IgG as a component of the comprehensive paraneoplastic neural antibody evaluation.
